74results about How to "Reduce reabsorption" patented technology

The present invention relates to dialysis solutions for peritoneal dialysis, containing hydroxyethyl starch as the osmotically-active substance, electrolytes and, optionally, conventional additives, where the hydroxyethyl starch has a molecular weight Mw in the range from 10,000 to 150,000, a substitution MS in the range from 0.10 to 0.40, a substitution DS in the range from 0.09 to 0.35 and a substitution ratio C2/C6>=8. With this peritoneal dialysis solution it is possible, with an outstanding ultrafiltration, to maintain a longer dwell time, for example the dialysis solution can be utilized for a period of 12 hours in the CAPD without replacement. In addition, the inventive dialysis solution is also particularly advantageous for patients with residual kidney function. The resorption of the osmotically active substance is clearly diminished and even after a dwell time of 12 hours it amounts to a maximum of 60-70%.

The slimming diet fiber biscuit is produced with flour and diet fiber as main material and supplementary material including salt, seasoning, etc. The diet fiber will expand after absorbing water and this makes the eater produce satiety to reduce the ingestion; and it will reduce the time for food to stay in intestinal tract to consume fat inside body and result in slimming effect. In addition, ingesting diet fiber can reduce the re-absorption amount and alter food digesting speed and digestion secretion amount to prevent gall stone, duodenal ulcer, peptic colonitis and other diseases.

A gallium nitride (GaN) based light emitting device, wherein the device comprises a first surface and a second surface, and the first surface and second surface are separated by a thickness of less than 100 micrometers, and preferably less than 20 micrometers. The first surface may be roughened or textured. A silver or silver alloy may be deposited on the second surface. The second surface of the device may be bonded to a permanent substrate.

A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.

The invention relates to an optical-fiber laser, in particular to a 1.7mum all-optical-fiber thulium-doped quartz optical-fiber laser based on a two-directional pumping structure. The 1.7mum all-optical-fiber thulium-doped quartz optical-fiber laser comprises a pumping source, an isolator and a laser resonance cavity, wherein the laser resonance cavity comprises an optical-fiber Bragg grating A, an optical-fiber Bragg grating B, an optical-fiber Bragg grating C, a wavelength division multiplexer and a thulium-doped quartz optical fiber. The 1.7mum all-optical-fiber thulium-doped quartz optical-fiber laser has the advantages that high-reflectivity optical-fiber grating at the wavelength position of the pumping source to reflect forward pumping light which cannot be completely absorbed back into the laser resonance cavity so as to form a simple and ingenious two-directional pumping structure. Due to the structure, the problem of low pumping-light absorbing efficiency caused by low doping concentration and short length of thulium-doped gain optical fiber can be effectively solved.

The present invention relates to light-converting materials which comprise semiconductor nanoparticles and an unactivated crystalline material, where the semiconductor nanoparticles are located on the surface of the unactivated crystalline material. The present invention furthermore relates to the use of the light-converting material in a light source. The present invention furthermore relates to a light-converting mixture, to a light source, to a lighting unit which contains the light-converting material according to the invention, and to a process for the production of the light source.

A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.

The present invention is light aggregate pre-treating process and apparatus. The light aggregate is first pressurized and humidified in a sealed pressure container as the light aggregate pre-treating apparatus in the pressure of 5-8 MPa for 30-120 min to reach water absorbing rate of 60-80 %; and then shell forming treated through mixing with cement for 90-180 min, with the cement adding amount being 50-100 kg for 1 cu m of aggregate without free water, to form watertight shell in the surface of the aggregate. The present invention has high aggregate pre-treating speed, high efficiency, and capacity keeping free water amount and maintaining high pumpability of the concrete.

The invention discloses an Sr and Mg doped amorphous apatite material and crystalline apatite material, belonging to the field of biomedical materials. The different concentrations of Sr and Mg doped amorphous apatite material is rapidly prepared by using Ca(NO3)2, Mg(NO3)2, Sr(NO3)2, (NH4)2HPO4 and ammonia-water as raw materials and then is transformed to the different concentrations of Sr and Mg doped nano calcium-deficient hydroxyapatite or nano tricalcium phosphate material through heat treatment. Compared with traditional hydroxyapatite crystalline materials, the amorphous material has higher solubility. The amorphous apatite material and the crystalline apatite material have the beneficial effects that after Sr and Mg doping, Sr can achieve the effects of promoting new bone formation, reducing reabsorption of bone, adjusting calcium metabolism and reducing the activity of osteoclast, and Mg can achieve the effects of affecting early growth of bone substances and regulating growth and remodelling of the bone substances; therefore the synthesized amorphous apatite and the crystallized product thereof have important roles in the fields of bone repair and bone transplantation.

The invention relates to a functional degreased sheep milk product and process for preparation, wherein the product is prepared from defatted sheep milk or its restored milk, soybean dietary fiber, fructooligosaccharide, xylitol, stabilizer, flavoring agent and water through steps of mixing homogeneously, dissolving, hydrating, homogenizing, sterilizing and packaging.

The invention belongs to the field of medicines or health products, and particularly relates to a novel use of sesquiterpenoid in reducing uric acid. The sesquiterpenoid has a structure represented byformula (I): wherein X, R1-R11 are as defined in the description of the invention. Through an animal model of hyperuricemia, the sesquiterpenoid of the invention is found to promote uric acid excretion in vivo, has an obvious effect of reducing uric acid, and can be used as a potential medicine for reducing uric acid or treating gout.

The invention belongs to the field of drugs or health care products, and particularly relates to new application of sesquiterpenoids to uric acid lowering. The sesquiterpenoids include the structure shown in a formula (I) (please see the specification for the formula (I)), wherein R1, R2, R3 and R4 are shown as definitions of a specification of the invention. Through a hyperuricemia animal model,it is found that the sesquiterpenoids promote uric acid excretion in vivo, has the significant uric acid lowering effect, and can serve as a potential drug for lowering uric acid or treating gout.

The invention provides a high-power LED packaging structure. The high-power LED packaging structure comprises a reflective cup and an integrated packaging substrate, wherein the reflective cup is a groove formed on the surface of the integrated packaging substrate; a lens is arranged at the upper end of the reflective cup; a bonding layer, an LED chip, a dispensing layer and a phosphor powder layer are sequentially arranged in a cavity formed by the lens and the reflective cup; and an electrode for connecting the LED chip and a drive circuit is arranged on the integrated packaging substrate. The LED packaging structure provided by the invention adopts integrated package to avoid heat dissipation bottleneck in traditional LEDs; and the layered dispensing layer enables the LED chip to be far away from the phosphor powder layer, so that light re-absorption of the LED chip in the traditional packaging structure is reduced, and the light emitting rate and the light distribution performance are improved. The LED packaging structure provided by the invention not only has a simple structure but also omits a bracket, an aluminum baseplate and a heat sink part in traditional package, thereby reducing the process steps, lowering the cost and facilitating industrial production.

Pharmaceutical formulations comprising raloxifene or its salts, esters, polymorphs, isomers, hydrates, solvates, or derivatives thereof having defined particle sizes. Also described are processes for preparing formulations and methods of using such formulations.

Peptidic dual GLP-1 / Glucagon Receptor Agonists derived from Exendin-4 The present invention relates to dual GLP-1 / glucagon receptor agonists or optionally trigonal GLP-1 / glucagon / GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

The invention provides a Chinese traditional medicine compound injection and preparation method, wherein the compound comprises Notoginsen triterpenes, ammonium glycyrrhizinato, sodium chloride, glucose, mannitol, lactose, sorbitol, dextran as the clinically accept, osmoregulation agent, freeze drying excipient and water for injection. The components can be prepared into injection, high volume injection and freeze dried injection.

The invention relates to a prebiotic composition containing inulin, and a preparation method and use of the composition. The prebiotic composition containing inulin prepared in the invention comprisesinulin, a traditional Chinese medicine extract and malt; the inulin is a mixture of GFn (n=2-60); and the traditional Chinese medicine extract is one or two of balsam pear extract or polygonatum extract, and the particle size is 40-60 mesh. The preparation method of the prebiotic composition containing inulin includes: (1) crushing and sieving the traditional Chinese medicine extract; (2) crushing and sieving the malt; (3) mixing the traditional Chinese medicine extract and the malt in equal increment to obtain a mixture A; (4) mixing the inulin and the mixture A evenly; and (5) conducting packing and sealing. According to the present invention, the prepared prebiotic composition containing inulin has a good synergistic effect of lowering blood sugar and blood lipid, can not only reduce the hyperglycemia of diabetic patients, but also reduce the complication hyperlipemia. At the same time, the probiotic composition has high safety, and does not cause allergic reaction due to the introduction of exogenous probiotics, and the preparation method is simple and easy.